Medical Devices Industry | Healthcare Sector | Mr. Anthony Fernando CEO | OTC PINK Exchange | - ISIN |
United States Country | 207 Employees | - Last Dividend | - Last Split | 12 Nov 1992 IPO Date |
Asensus Surgical, Inc. is at the forefront of the medical device industry, focusing on the development and commercialization of robotics designed to enhance minimally invasive surgery (MIS). With operations spreading across the United States, Europe, the Middle East, Africa, and Asia, the company aims to revolutionize the way surgical procedures are performed. By digitizing the interface between surgeons and patients, Asensus Surgical facilitates performance-guided surgery, allowing surgeons to achieve improved outcomes for their patients. Originally known as TransEnterix, Inc., the company underwent a name change to Asensus Surgical, Inc. in February 2021, marking a new chapter in its mission to advance surgical technology. Its corporate headquarters are located in Durham, North Carolina.
The product portfolio of Asensus Surgical, Inc. is centered around the Senhance System and accompanying surgical tools and devices, which represent groundbreaking advancements in the field of robotic-assisted surgery:
This multi-port robotic surgery system empowers surgeons by providing up to four robotic arms that control various surgical instruments and a camera. Designed specifically for laparoscopic procedures, the Senhance System integrates seamlessly into existing hospital infrastructures, allowing for minimally invasive surgeries with precision and control unheard of with traditional manual techniques.
Asensus Surgical offers a range of specialized surgical instruments compatible with the Senhance System. These include instruments with a small diameter of 3mm and versatile hooks available in both 3mm and 5mm sizes. Additionally, the company provides articulating instruments that enhance the flexibility and reach of the robotic arms during procedures, enabling surgeons to perform complex maneuvers with ease.
An advanced energy device, the Senhance ultrasonic system, is designed for surgical procedures requiring the ligation and division of tissue. It delivers controlled energy, allowing for precise cutting and coagulation, which are critical for minimizing intra-operative blood loss and improving surgical outcomes. This system complements the Senhance System, further extending the capabilities of robotic-assisted surgery.